RevOpsis Therapeutics
RevOpsis Therapeutics is a pre-clinical biotech using its proprietary RevMod multispecific antibody platform to develop therapeutics for retinal vascular diseases, with lead asset RO-104 targeting wet AMD and diabetic eye disease for patients who respond suboptimally to current anti-VEGF therapies.
- Company typePrivate
- Founded2018
- HeadquartersSpringfield, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What RevOpsis Therapeutics does
RevOpsis Therapeutics is a private, pre-clinical biotechnology company developing multispecific biologic therapeutics, with an initial focus on retinal vascular diseases that cause vision loss. The company is built around its proprietary RevMod Platform, a modular plug-and-play discovery engine derived from Surrobody technology that leverages a structured phage display library of nearly 30 billion fully human antibody components. This platform produces customizable MultiMod biologics in BiMod (2 targets), TriMod (3 targets), and TetraMod (4+ targets) formats, anchored by a fully human universal light chain intended to maximize drug-like properties. The lead asset, RO-104, is a first-in-class TriMod biologic that simultaneously delivers pan-VEGF blockade and Ang-2 inhibition, positioning it against wet age-related macular degeneration (nAMD), diabetic eye disease, and related retinal vascular conditions where roughly 70% of nAMD patients respond suboptimally to current VEGF-A monotherapies.
The company operates a B2B platform-plus-partner model. It does not sell approved products and is pre-revenue; capital formation to date comprises a $7.9M securities offering (2023), an approximately $9M equity round (April 2024), a $1.8M NEI SBIR grant (October 2024), and a strategic investment from ophthalmology-focused ExSight Ventures (September 2025). Manufacturing and commercialization in India are handled through an exclusive agreement with Kemwell Biopharma, while R&D operations sit at MBC BioLabs in San Carlos, California, with the corporate headquarters in Springfield, Illinois. Leadership is led by co-founder and CEO Dr. Ramanath Bhandari (vitreoretinal surgeon) with CSO Dr. Ramesh Bhatt (formerly of Janux Therapeutics and Protagonist) and CBO Ronil Patel (track record of raising over $100M and exits above $500M). Future revenue mechanics are expected to flow from licensing royalties, co-development partnerships, and the Kemwell commercial arrangement once RO-104 advances into and through clinical trials, currently targeted to start in late 2025.
RevOpsis Therapeutics firmographics
Firmographics- Name
- RevOpsis Therapeutics
- Legal name
- RevOpsis Therapeutics, Inc.
- Website
- https://revopsis.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- RevOpsis Therapeutics is a pre-clinical biotech using its proprietary RevMod multispecific antibody platform to develop therapeutics for retinal vascular diseases, with lead asset RO-104 targeting wet AMD and diabetic eye disease for patients who respond suboptimally to current anti-VEGF therapies.
- Ownership category
- akta.pro rank
RevOpsis Therapeutics industry classification
Industry- Product category
- Ophthalmic Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where RevOpsis Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Springfield
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
RevOpsis Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Revenue model
- Biopharmaceutical Development & Commercialization: RevOpsis is a pre-revenue biotech company developing novel therapeutics. The company will generate revenue through licensing agreements, co-development partnerships, and eventual commercialization of its pipeline candidates including RO-104 for retinal vascular diseases. Partnerships with CDMOs like Kemwell support manufacturing for specific markets.
- Grant Funding (NIH/NEI): The company receives non-dilutive funding through SBIR grants from the National Eye Institute (NEI) to support R&D activities for lead asset RO-104, including preclinical toxicology studies advancing toward IND application.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
RevOpsis Therapeutics product offering
Product offeringCore offering
RevOpsis Therapeutics develops novel multispecific biologics for retinal vascular diseases using its proprietary RevMod Platform, a modular plug-and-play antibody discovery system. Its lead therapeutic candidate RO-104 is a first-in-class TriMod biologic that simultaneously provides pan-VEGF blockade and Ang-2 inhibition for treating wet AMD and diabetic eye disease. The company generates value through licensing, co-development partnerships, and eventual commercialization of its pipeline candidates.
Product overview
RevOpsis Therapeutics operates a platform-plus-products model centered on its proprietary RevMod Platform, a modular plug-and-play system for developing multispecific biologics. The core product is RO-104, a first-in-class TriMod biologic targeting retinal vascular diseases including wet AMD and diabetic eye disease. The platform enables development of various MultiMod biologic formats (BiMod, TriMod, TetraMod) for multiple therapeutic areas including ophthalmology, oncology, and immune-mediated diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- RO-104 First-in-class, fully human TriMod biologic therapeutic candidate developed using the RevMod Platform to treat retinal vascular diseases including wet age-related macular degeneration (nAMD) and diabetic eye disease. RO-104 simultaneously provides pan-VEGF blockade while inhibiting Ang-2, targeting 3 distinct pathways with matched high affinity to address multifactorial retinal disease.
Quantifiable outcome
- RO-104 demonstrates intended efficacy in established animal models compared to approved anti-VEGF therapeutics such as Eylea and Vabysmo
Companies that use RevOpsis Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
RevOpsis Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
RevOpsis Therapeutics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- Kemwell BiopharmacoreKemwell is the leading biologics CDMO in Asia, providing end-to-end development and manufacturing services for mammalian cell culture-based products. They are the exclusive partner for manufacturing and commercialization of RO-104 for the Indian market, with cGMP facilities including over 5000L bioreactor capacity.
- MBC BioLabsminorMBC BioLabs provides RevOpsis with flexible and cost-effective lab space, scientific equipment, and comprehensive operational support at their San Carlos, California location. The facilities are innovation hubs supporting startups in the life sciences.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
RevOpsis Therapeutics competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat5 records
Customer concentration
RevOpsis Therapeutics social profiles
Digital presenceRevOpsis Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
RevOpsis Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
RevOpsis Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RevOpsis Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RevOpsis Therapeutics
What does RevOpsis Therapeutics do?
RevOpsis Therapeutics develops novel multispecific biologics for retinal vascular diseases using its proprietary RevMod Platform, a modular plug-and-play antibody discovery system. Its lead therapeutic candidate RO-104 is a first-in-class TriMod biologic that simultaneously provides pan-VEGF blockade and Ang-2 inhibition for treating wet AMD and diabetic eye disease. The company generates value through licensing, co-development partnerships, and eventual commercialization of its pipeline candidates.
Is RevOpsis Therapeutics a public or private company?
RevOpsis Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was RevOpsis Therapeutics founded?
RevOpsis Therapeutics was founded in 2018. It employs 1 to 10 people.
Where is RevOpsis Therapeutics based?
RevOpsis Therapeutics is headquartered in Springfield, United States, in the North America region.
How does RevOpsis Therapeutics make money?
Two revenue lines are on record. Biopharmaceutical Development & Commercialization is the primary driver. The others are grant Funding (NIH/NEI).
Does RevOpsis Therapeutics have an API?
No public API is recorded for RevOpsis Therapeutics.
What industry is RevOpsis Therapeutics in?
RevOpsis Therapeutics's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 541714 and its SIC code is 2836.